C
CGTX icon

Chescapmanager’s Cognition Therapeutics CGTX Stock Holding History

Chescapmanager’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$757K Hold
997,029
– – 0.07% 27
2025
Q4 		$1.35M Hold
997,029
– – 0.11% 25
2025
Q3 		$1.35M Buy
997,029
+493,770
+98% +$673K 0.13% 22
2025
Q2 		$156K Buy
+503,259
New +$170K 0.02% 24

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Chescapmanager's CGTX Position: Q1 2026 in Review

Chescapmanager held its Cognition Therapeutics (CGTX) position steady in Q1 2026 at 997,029 shares worth $757K. The position accounts for 0.07% of the portfolio, ranked #27.

Chescapmanager first reported a position in CGTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.35M in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Chescapmanager held 997,029 shares of Cognition Therapeutics worth $757K as of Q1 2026.
  • Chescapmanager left its Cognition Therapeutics share count unchanged in Q1 2026.
  • Cognition Therapeutics made up 0.07% of Chescapmanager's portfolio in Q1 2026, its #27 holding.
  • Chescapmanager first reported a position in Cognition Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Chescapmanager's Cognition Therapeutics position peaked at $1.35M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Chescapmanager's 13F filing for Q1 2026, filed 14 May 2026.